Detalhe da pesquisa
1.
Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
Gynecol Oncol
; 133(3): 446-53, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24657302
2.
Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany.
J Med Econ
; 27(1): 39-50, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38050685
3.
The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan.
Vaccines (Basel)
; 12(4)2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38675816
4.
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States.
J Med Econ
; 26(1): 1532-1545, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37961887
5.
The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States.
J Med Econ
; 25(1): 1127-1139, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36184797
6.
A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.
Pharmacoeconomics
; 38(6): 607-618, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32157590
7.
Cost per response analysis of strategies for chronic immune thrombocytopenia.
Am J Manag Care
; 24(8 Spec No.): SP294-SP302, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30020741
8.
Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Pharmacoeconomics
; 35(4): 425-438, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27928760
9.
Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.
Expert Rev Pharmacoecon Outcomes Res
; 17(1): 39-52, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28064553
10.
Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
J Med Econ
; 17(1): 32-42, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24028444